- Trial phase
- Approved
- Time to market
- Already approved and marketed in the U.S. since September 2016.
- Why 4/10
- EXONDYS 51 is already approved and commercialized with no pending regulatory decision or pivotal readout for the drug itself. The next hard catalyst is the January 21, 2027 PDUFA date for Dyne Therapeutics' competing exon 51 drug z-rostudirsen, which is a competitive event rather than a catalyst for EXONDYS 51. Per the rubric, an approved drug with no upcoming binary catalyst scores 3-5; EXONDYS 51 is one of several products in Sarepta's portfolio, so it scores a 4.
The next major catalyst for EXONDYS 51 is not a regulatory decision on the drug itself (already approved), but the January 21, 2027 PDUFA date for Dyne Therapeutics' competing exon 51 DMD drug z-rostudirsen. An approval would introduce direct competition to EXONDYS 51's core market. Separately, watch for Sarepta's quarterly revenue trends for the exon-skipping franchise and any updates on confirmatory trial data that could convert EXONDYS 51 from accelerated to traditional approval.
Price Chart
Executive Summary
EXONDYS 51 (eteplirsen) is Sarepta Therapeutics' first-in-class antisense oligonucleotide for Duchenne muscular dystrophy (DMD) patients with exon 51 skipping-amenable mutations, approved by the FDA under accelerated approval in September 2016. It is a marketed, revenue-generating product and part of Sarepta's broader exon-skipping franchise (alongside AMONDYS 45 and VYONDYS 53). The drug faces a looming competitive threat: Dyne Therapeutics' z-rostudirsen, targeting the same exon 51 population, has a PDUFA target action date of January 21, 2027 under priority review. Sarepta reported Q3 2026 total revenue of $381.35 million and narrowed its 2026 product revenue guidance to $1.25-$1.3 billion, citing continued strength in its exon-skipping franchise. With no pending regulatory catalyst for EXONDYS 51 itself, the stock's next major binary event is the competitive PDUFA decision in early 2027.
How It Works
EXONDYS 51 is an antisense oligonucleotide, a short synthetic piece of genetic material designed to bind to a specific section of the dystrophin gene (exon 51). In Duchenne muscular dystrophy patients whose genetic mutation makes them candidates for exon 51 skipping, the drug effectively "hides" that exon during protein production, allowing the cell to skip over the faulty section and produce a shortened but still functional version of the dystrophin protein. This protein is essential for muscle cell integrity, and its absence causes the progressive muscle degeneration seen in DMD.
Trial Status
EXONDYS 51 was granted accelerated FDA approval in September 2016 for DMD patients with exon 51 skipping-amenable mutations, based on dystrophin production as a surrogate endpoint. Confirmatory post-marketing trials are ongoing to verify clinical benefit. The drug is commercially marketed in the U.S. and generated revenue as part of Sarepta's exon-skipping franchise, which the company cited as showing continued strength in its Q3 2026 earnings report.
The Two-Sided Case
Upcoming Catalysts
- January 21, 2027: PDUFA target action date for Dyne Therapeutics' competing exon 51 DMD drug z-rostudirsen (priority review). An approval would introduce direct competition to EXONDYS 51.
- Ongoing: Confirmatory post-marketing trial data for EXONDYS 51 that could support conversion from accelerated to traditional FDA approval.
- Quarterly: Sarepta's exon-skipping franchise revenue trends in upcoming earnings reports.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sarepta Therapeutics, Inc. 8-K SRPT ·Originating report